1. We have a rigorous validation plan for ensuring that the applications on the platform perform robustly. We also operate in an industry where the standards are very high and samples being processed are previous and there are no excuses for failures. Moreover we have deployed with several customers in 2023, results of which have been showcased at premier genomics conference like AGBT. They are all published on our website here: https://www.voltalabs.com/resources

2. Some technical limitations of the platform include its inability to do PCR or onboard implication, there are also limitations on range of volumes we can work with. We plan to address these in the future.

3. Our system actually leverages an advanced form of electrowetting, magnetic manipulation of samples and thermal control in combination with liquid transfer technologies like pipettors. Our roadmap includes advancing all of these underlying technologies: for example being able to go to higher or lower temperatures. If you also think about the declining cost of sequencing, the cost of sample prep needs to go down relative to the cost of sequencing: we are going to advance the technology to drive the cost curve down. We might potentially expand into other applications beyond sequencing: those include synthetic biology, proteomics to name a couple.